Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsKYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.
Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.
MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN
AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies
Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day
The HCPFive: Top News for Healthcare Providers from the Week of 11/16
1.
Treatment of Smoldering Myeloma Cuts Progression Rate in Half
2.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
3.
Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A
4.
Routine breast cancer screening can bring better outcomes for patients
5.
Parkinson patient's gait is restored by a spinal cord stimulator.
1.
Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients
2.
Examining Serum Osmolality: What It Is And How To Test For It
3.
Hypercoagulable State: Factors that Contribute to Blood Clots
4.
Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier
5.
Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
4.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge